MedTrace Logo

Long-term Follow-up of Measles Antibodies

NCT00168571 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1960

Last updated 2011-09-22

No results posted yet for this study

Summary

Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would be the first to describe the persistence of measles antibodies after two doses of measles vaccine, and the study would allow us to identify unprotected children and offer them revaccination. Since persistence of measles antibodies is of crucial importance to measles control, the study will contribute significantly to the existing knowledge and might have important implications for future eradication programmes.

Conditions

Interventions

BIOLOGICAL

Measles vaccine

Sponsors & Collaborators

  • Danish Council for Development Research

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Fonden til Lægevidenskabens Fremme

    collaborator OTHER

  • Medical Research Council Unit, The Gambia

    collaborator OTHER

  • Bandim Health Project

    lead OTHER

Principal Investigators

  • PETER AABY, MSc, Dr Med · Bandim Health Project

  • MAY-LILL GARLY, PHD, DTM&H · Bandim Health Project

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-03-31
Completion
2007-01-31

Countries

  • Guinea-Bissau

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168571 on ClinicalTrials.gov